Brief: Medicenna Strengthens Intellectual Property Protection For Superkine Platform With Issuance Of U.S. Patent
09/06/2022 13:12
June 9 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA STRENGTHENS INTELLECTUAL PROPERTY PROTECTION FOR
SUPERKINE PLATFORM WITH ISSUANCE OF U.S. PATENT
* MEDICENNA THERAPEUTICS CORP- PATENT COVERS COMPOSITION AND
METHODS OF TREATING DEGENERATIVE DISEASES VIA ADMINISTRATION OF
IL-4 AND IL-13 EMPOWERED SUPERKINES
* MEDICENNA THERAPEUTICS CORP- PATENT'S TERM EXTENDS INTO AT
LEAST
2038 WITHOUT ACCOUNTING FOR ANY POTENTIAL EXTENSIONS
Source text for Eikon: ID:nGNXb7flmc
Further company coverage: MDNA.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results